Duration of Analgesia With Dexmedetomidine and Ropivacaine in Brachial Plexus Block

University of Florida

Status and phase: Withdrawn; Phase 4

Conditions: Peripheral Nerve Block; Pain, Acute; Analgesia

Treatments: Drug: Dexmedetomidine; Drug: ropivacaine

Study type: Interventional

Funder types: Other

Identifiers

NCT03385967

IRB201702926

Details and patient eligibility

About

This is a prospective, randomized, double blind study of adding dexmedetomidine to ropivacaine for Brachial plexus block and assessing the analgesia with VAS pain scales(0-10), Satisfaction scale by VAS scale(0-10) and time to first analgesic consumption. This study mainly aims to investigate whether addition of dexmedetomidine helps in increasing the duration of analgesia.

Full description

In our institute ropivacaine is used for all the peripheral nerve blocks. This a prospective, randomized, double blind clinical trial study comparing the addition of dexmedetomidine vs ropivacaine alone in brachial plexus nerve block. After screening the patient with the inclusion criteria, an informed consent is obtained from the patient by one of the co-investigator.

Adjuvants to local anesthetics are commonly added to prolong the duration of the peripheral nerve block. Sometimes patients have other added comorbidities along with high BMI with history of chronic pain where prolonging the duration of the peripheral nerve block would help with decreased narcotic consumption in the perioperative period with minimal side effects related to the local anesthetics(LA) as well as the adjuncts.

Dexmedetomidine is proven to be better than Clonidine in a recent study. Also perineural dexmedetomidine is proven to be more efficacious compared to intravenous dosing. The investigators are evaluating whether adding dexmedetomidine to standard dose of Ropivacaine helps in prolonging the duration of the peripheral nerve block with minimal side effects.

Sex: All

Ages: 18 to 99 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Age-18years and above
• Both male and female patients
• BMI->18
• Elective Subacute upper extremity fractures

Exclusion criteria

• Chronic pain patients (Pain persisting for more than 3-6months or past the normal healing time of any injury, influences every aspect of a person's quality of life.)
• Patients with drug abuse history in the past 6 months
• ESRD
• Hepatic failure

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

0 participants in 2 patient groups

ropivacaine only

Active Comparator group

Description:

0.5% ropivacaine

Treatment:

Drug: ropivacaine

ropivacaine with dexmedetomidine

Active Comparator group

Description:

25ml of 0.5%ropivacaine with 0.25mcg/kg of dexmedetomidine

Treatment:

Drug: ropivacaine

Drug: Dexmedetomidine